当前位置: 首页 >> 检索结果
141. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans.
作者: Mikkel Christensen.;Louise Vedtofte.;Jens J Holst.;Tina Vilsbøll.;Filip K Knop.
来源: Diabetes. 2011年60卷12期3103-9页
To evaluate the glucose dependency of glucose-dependent insulinotropic polypeptide (GIP) effects on insulin and glucagon release in 10 healthy male subjects ([means ± SEM] aged 23 ± 1 years, BMI 23 ± 1 kg/m(2), and HbA(1c) 5.5 ± 0.1%).
142. Vitamin D, insulin secretion, sensitivity, and lipids: results from a case-control study and a randomized controlled trial using hyperglycemic clamp technique.
Vitamin D deficiency is associated with an unfavorable metabolic profile in observational studies. The intention was to compare insulin sensitivity (the primary end point) and secretion and lipids in subjects with low and high serum 25(OH)D (25-hydroxyvitamin D) levels and to assess the effect of vitamin D supplementation on the same outcomes among the participants with low serum 25(OH)D levels.
143. C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study.
作者: Raffaella Buzzetti.;Simona Cernea.;Antonio Petrone.;Marco Capizzi.;Marialuisa Spoletini.;Simona Zampetti.;Chiara Guglielmi.;Chiara Venditti.;Paolo Pozzilli.; .
来源: Diabetes. 2011年60卷11期3067-72页
To investigate whether lower risk HLA class II genotypes would influence the efficacy of DiaPep277 therapy in protecting β-cell function evaluated by C-peptide secretion in recent-onset type 1 diabetic subjects.
144. Rituximab selectively suppresses specific islet antibodies.
作者: Liping Yu.;Kevan Herold.;Heidi Krause-Steinrauf.;Paula L McGee.;Brian Bundy.;Alberto Pugliese.;Jeff Krischer.;George S Eisenbarth.; .
来源: Diabetes. 2011年60卷10期2560-5页
The TrialNet Study Group evaluated rituximab, a B-cell-depleting monoclonal antibody, for its effect in new-onset patients with type 1A diabetes. Rituximab decreased the loss of C-peptide over the first year of follow-up and markedly depleted B lymphocytes for 6 months after administration. This article analyzes the specific effect of rituximab on multiple islet autoantibodies.
145. Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance.
作者: Hyun-Seuk Moon.;Giuseppe Matarese.;Aoife M Brennan.;John P Chamberland.;Xiaowen Liu.;Christina G Fiorenza.;Geetha H Mylvaganam.;Luisa Abanni.;Fortunata Carbone.;Catherine J Williams.;Alex M De Paoli.;Benjamin E Schneider.;Christos S Mantzoros.
来源: Diabetes. 2011年60卷6期1647-56页
Metreleptin has been efficacious in improving metabolic control in patients with lipodystrophy, but its efficacy has not been tested in obese patients with type 2 diabetes.
146. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans.
Glucagon-like peptide (GLP)-1 lowers postprandial glycemia primarily through inhibition of gastric emptying. We addressed whether the GLP-1-induced deceleration of gastric emptying is subject to rapid tachyphylaxis and if so, how this would alter postprandial glucose control.
147. Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.
作者: Steven E Kahn.;John M Lachin.;Bernard Zinman.;Steven M Haffner.;R Paul Aftring.;Gitanjali Paul.;Barbara G Kravitz.;William H Herman.;Giancarlo Viberti.;Rury R Holman.; .
来源: Diabetes. 2011年60卷5期1552-60页
ADOPT (A Diabetes Outcome Progression Trial) demonstrated that initial monotherapy with rosiglitazone provided superior durability of glycemic control compared with metformin and glyburide in patients with recently diagnosed type 2 diabetes. Herein, we examine measures of β-cell function and insulin sensitivity from an oral glucose tolerance test (OGTT) over a 4-year period among the three treatments.
148. Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes.
作者: Bettina Mittendorfer.;Jeffrey F Horowitz.;Alex M DePaoli.;Mark A McCamish.;Bruce W Patterson.;Samuel Klein.
来源: Diabetes. 2011年60卷5期1474-7页
Leptin therapy improves insulin sensitivity in people with leptin deficiency, but it is not known whether it improves insulin action in people who are not leptin deficient. The purpose of the current study was to determine whether leptin treatment has weight loss-independent effects on insulin action in obese subjects with type 2 diabetes.
149. Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program.
作者: Marie-France Hivert.;Kathleen A Jablonski.;Leigh Perreault.;Richa Saxena.;Jarred B McAteer.;Paul W Franks.;Richard F Hamman.;Steven E Kahn.;Steven Haffner.; .;James B Meigs.;David Altshuler.;William C Knowler.;Jose C Florez.; .
来源: Diabetes. 2011年60卷4期1340-8页
Over 30 loci have been associated with risk of type 2 diabetes at genome-wide statistical significance. Genetic risk scores (GRSs) developed from these loci predict diabetes in the general population. We tested if a GRS based on an updated list of 34 type 2 diabetes-associated loci predicted progression to diabetes or regression toward normal glucose regulation (NGR) in the Diabetes Prevention Program (DPP).
150. Partial inhibition of insulin secretion results in glucose intolerance but not hyperglucagonemia.
We tested the hypotheses that in nondiabetic individuals, partial inhibition of insulin secretion with the ATP-sensitive K(+) channel agonist (opener) diazoxide, compared with placebo, results in higher plasma glucose and higher plasma glucagon concentrations after a mixed meal and after administration of the sulfonylurea glimepiride.
151. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes.
作者: Nikolaos Mentis.;Irfan Vardarli.;Lars D Köthe.;Jens J Holst.;Carolyn F Deacon.;Michael Theodorakis.;Juris J Meier.;Michael A Nauck.
来源: Diabetes. 2011年60卷4期1270-6页
The incretin glucagon-like peptide 1 (GLP-1) exerts insulinotropic activity in type 2 diabetic patients, whereas glucose-dependent insulinotropic polypeptide (GIP) no longer does. We studied whether GIP can alter the insulinotropic or glucagonostatic activity of GLP-1 in type 2 diabetic patients.
152. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes.
作者: Spiros Fourlanos.;Christine Perry.;Shane A Gellert.;Emanuela Martinuzzi.;Roberto Mallone.;Jeanne Butler.;Peter G Colman.;Leonard C Harrison.
来源: Diabetes. 2011年60卷4期1237-45页
Insulin in pancreatic β-cells is a target of autoimmunity in type 1 diabetes. In the NOD mouse model of type 1 diabetes, oral or nasal administration of insulin induces immune tolerance to insulin and protects against autoimmune diabetes. Evidence for tolerance to mucosally administered insulin or other autoantigens is poorly documented in humans. Adults with recent-onset type 1 diabetes in whom the disease process is subacute afford an opportunity to determine whether mucosal insulin induces tolerance to insulin subsequently injected for treatment.
153. Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial.
作者: Jack A Yanovski.;Jonathan Krakoff.;Christine G Salaita.;Jennifer R McDuffie.;Merel Kozlosky.;Nancy G Sebring.;James C Reynolds.;Sheila M Brady.;Karim A Calis.
来源: Diabetes. 2011年60卷2期477-85页
Metformin can decrease adiposity and ameliorate obesity-related comorbid conditions, including abnormalities in glucose homeostasis in adolescents, but there are few data evaluating the efficacy of metformin among younger children. Our objective was to determine whether metformin treatment causes weight loss and improves obesity-related comorbidities in obese children, who are insulin-resistant.
154. Coffee and caffeine consumption in relation to sex hormone-binding globulin and risk of type 2 diabetes in postmenopausal women.
作者: Atsushi Goto.;Yiqing Song.;Brian H Chen.;JoAnn E Manson.;Julie E Buring.;Simin Liu.
来源: Diabetes. 2011年60卷1期269-75页
Coffee consumption has been inversely associated with type 2 diabetes risk, but its mechanisms are largely unknown. We aimed to examine whether plasma levels of sex hormones and sex hormone-binding globulin (SHBG) may account for the inverse association between coffee consumption and type 2 diabetes risk.
155. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes.
作者: Maria F Lopes-Virella.;Kelly J Hunt.;Nathaniel L Baker.;John Lachin.;David M Nathan.;G Virella.; .
来源: Diabetes. 2011年60卷2期582-9页
High cholesterol levels in circulating immune complexes (IC), surrogate markers of modified LDL, are associated with increased carotid intima-media thickness (IMT) and cardiovascular events in type 1 diabetes. Different modifications of LDL are involved in IC formation, but which of these are predictive of vascular events is not known. Therefore, we measured oxidized LDL (oxLDL), advanced glycation end products-modified LDL (AGE-LDL), and malondialdehyde-modified LDL (MDA-LDL) in IC and determined their relationship with increased carotid IMT and compared the strength of the association with that observed with conventional risk factors.
156. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program.
作者: Kathleen A Jablonski.;Jarred B McAteer.;Paul I W de Bakker.;Paul W Franks.;Toni I Pollin.;Robert L Hanson.;Richa Saxena.;Sarah Fowler.;Alan R Shuldiner.;William C Knowler.;David Altshuler.;Jose C Florez.; .
来源: Diabetes. 2010年59卷10期2672-81页
Genome-wide association studies have begun to elucidate the genetic architecture of type 2 diabetes. We examined whether single nucleotide polymorphisms (SNPs) identified through targeted complementary approaches affect diabetes incidence in the at-risk population of the Diabetes Prevention Program (DPP) and whether they influence a response to preventive interventions.
157. Sleep restriction for 1 week reduces insulin sensitivity in healthy men.
作者: Orfeu M Buxton.;Milena Pavlova.;Emily W Reid.;Wei Wang.;Donald C Simonson.;Gail K Adler.
来源: Diabetes. 2010年59卷9期2126-33页
Short sleep duration is associated with impaired glucose tolerance and an increased risk of diabetes. The effects of sleep restriction on insulin sensitivity have not been established. This study tests the hypothesis that decreasing nighttime sleep duration reduces insulin sensitivity and assesses the effects of a drug, modafinil, that increases alertness during wakefulness.
158. Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women.
作者: Marleen Kars.;Ling Yang.;Margaret F Gregor.;B Selma Mohammed.;Terri A Pietka.;Brian N Finck.;Bruce W Patterson.;Jay D Horton.;Bettina Mittendorfer.;Gökhan S Hotamisligil.;Samuel Klein.
来源: Diabetes. 2010年59卷8期1899-905页
Insulin resistance is commonly associated with obesity. Studies conducted in obese mouse models found that endoplasmic reticulum (ER) stress contributes to insulin resistance, and treatment with tauroursodeoxycholic acid (TUDCA), a bile acid derivative that acts as a chemical chaperone to enhance protein folding and ameliorate ER stress, increases insulin sensitivity. The purpose of this study was to determine the effect of TUDCA therapy on multiorgan insulin action and metabolic factors associated with insulin resistance in obese men and women.
159. A prospective analysis of elevated fasting glucose levels and cognitive function in older people: results from PROSPER and the Rotterdam Study.
作者: Sjoerd M Euser.;Naveed Sattar.;Jacqueline C M Witteman.;Eduard L E M Bollen.;Eric J G Sijbrands.;Albert Hofman.;Ivan J Perry.;Monique M B Breteler.;Rudi G J Westendorp.; .
来源: Diabetes. 2010年59卷7期1601-7页
To investigate the relationship between fasting glucose levels, insulin resistance, and cognitive impairment in old age. Diabetes is associated with cognitive impairment in older people. However, the link between elevated fasting glucose levels and insulin resistance in nondiabetic individuals, and the risk of cognitive impairment is unclear.
160. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans.
作者: Benjamin C T Field.;Alison M Wren.;Veronique Peters.;Kevin C R Baynes.;Niamh M Martin.;Michael Patterson.;Sara Alsaraf.;Vian Amber.;Katie Wynne.;Mohammad A Ghatei.;Stephen R Bloom.
来源: Diabetes. 2010年59卷7期1635-9页
Peptide YY(3-36) (PYY(3-36)), a Y2 receptor agonist, and oxyntomodulin, a glucagon-like peptide 1 (GLP-1) receptor agonist, are cosecreted by intestinal L-cells after each meal. Separately each hormone acts as an endogenous satiety signal and reduces appetite in humans when infused intravenously. The aim of the current study was to investigate whether the anorectic effects of PYY(3-36) and oxyntomodulin can be additive.
|